Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Författare
Summary, in English
Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We reasoned that a radiotracer targeting a validated clinical biomarker could more clearly assess the advantages of imaging cancer. The virtues and shortcomings of measuring secreted prostate-specific antigen (PSA), an androgen receptor (AR) target gene, in patients with prostate cancer are well documented, making it a logical candidate for assessing whether a radiotracer can reveal new (and useful) information beyond that conferred by serum PSA. Therefore, we developed (89)Zr-labeled 5A10, a novel radiotracer that targets "free" PSA. (89)Zr-5A10 localizes in an AR-dependent manner in vivo to models of castration-resistant prostate cancer, a disease state in which serum PSA may not reflect clinical outcomes. Finally, we demonstrate that (89)Zr-5A10 can detect osseous prostate cancer lesions, a context where bone scans fail to discriminate malignant and nonmalignant signals.
Avdelning/ar
- Klinisk kemi, Malmö
- Urologisk cancerforskning, Malmö
- Urological research, Malmö
- EpiHealth: Epidemiology for Health
Publiceringsår
2012
Språk
Engelska
Sidor
320-327
Publikation/Tidskrift/Serie
Cancer Discovery
Volym
2
Issue
4
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
American Association for Cancer Research
Ämne
- Cancer and Oncology
Status
Published
Forskningsgrupp
- Clinical Chemistry, Malmö
- Urological cancer, Malmö
- Urological research, Malmö
ISBN/ISSN/Övrigt
- ISSN: 2159-8274